This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

PITCH PILOT

  • Research type

    Research Study

  • Full title

    Prospective Interruption of Therapy towards a Cure for HIV (PITCH) Pilot Study

  • IRAS ID

    191612

  • Contact name

    John Frater

  • Contact email

    john.frater@ndm.ox.ac.uk

  • Sponsor organisation

    University of Oxford

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    Drugs for HIV infection are effective at keeping the virus at bay, but are not a cure. Scientists have discovered that if patients start treatment within a few months of being infected, a significant proportion (up to 14%) enter a state of remission in which HIV stays undetectable and patients remain well if they stop treatment. Some patients have been off treatment for as much as 10 years. This condition - called ‘post treatment control’ (or ‘PTC’) - challenges our understanding of the relationship between HIV and man. We do not understand how much treatment is necessary, when it should be started and if there are laboratory markers that can help predict reaching this state.

    In this pilot, we aim to stop treatment in HIV positive volunteers who started being treated very early to discover how many will reach PTC and what might be causing it. We will monitor these volunteers closely for evidence of returning virus and see how their immune system is responding and, crucially, how much of an impact this is having on the HIV ‘reservoir’ (sleeping viruses that remain dormant while people are on treatment). The idea is, because we are starting treatment very early, HIV will not have had as much chance to have a large reservoir and so we have a good chance of reducing it. If HIV returns, volunteers will be immediately restarted on treatment, thereby avoiding any harm. We aim to identify patients who can stop treatment for years, and some who may never need to be treated again. The health-related, psychological and economic implications of this are substantial. Additionally, understanding the mechanism of PTC will help develop new treatments that might allow others patients to stop treatment and enter long term remission, or even cure.

  • REC name

    South Central - Oxford C Research Ethics Committee

  • REC reference

    16/SC/0338

  • Date of REC Opinion

    1 Jul 2016

  • REC opinion

    Favourable Opinion